phoenestra

EVscale[™] - Scalability and Consistency for the Future of Extracellular Vesicles / Exosomes

Phoenestra GmbH March 2024

The Challenge with Extracellular Vesicles (EV) and how Phoenestra has addressed it



Problem Statement

- Primary MSC are highly variable
- Extracellular Vesicles (EV) / exosomes from primary MSC are highly variable
- Scalability issues
- Intrinsic complexity
- All this impacting clinical supplies and translation into clinical efficacy

Our Approach

- Stable MSC lines (MSC/TERT)
- Xeno- and Virus-free
- MCB/WCB concept
- Scalable Bioreactor technology and Downstreamprocessing
- Advanced analytical methods and approaches to address EV complexity

The Solution*: EVscale™

- Library of MSC/TERT lines from different human tissues (GMP-ready)
- Patented, scalable bioreactor setup for adherent cell lines
- Scalable Downstream
 processing
- Functional bioassays (Potency)
- -omics-based compositionfunction relationships



The Key Benefits of EVscale™

- ✓ Stable GMP-grade MSC lines (MSC/TERT) (licensed from Evercyte)
- Oncogene and virus-free cell line generation
- ✓ Tiered Cell Banking possible (MCB/WCB concept)
- Xeno-free and serum-free cultivation media
- High productivity from small bioreactor footprints which is scalable
- Gentle and scalable Downstream processing of EV / exosomes
- Proven biological functionalities, in-depth characterization (with Evercyte, TAmiRNA)

Less Variability and Better Consistency, Scalability and high Productivity Compared to Conventional MSC-EV Technologies








The EVscale[™] Platform Technology

The Importance of Advanced Manufacturing Technologies

- State-of-the-art unit operations which are scalable
- Perfusion bioreactor cultivation ensures **controlled** nutrient supply, metabolite removal and continuous EV harvest
- Membrane and chromatography-based Downstream processing for defined EV / exosome preparations
- Systematic process and analytical development
- Basis for successful translation into clinical efficacy
- Basis for cost leadership




Patent Pending

The EVscale[™] Platform Technology – Consistency and Scalability by Design

What differentiates EVscale[™] from other EV production technologies? Clinical and commercial success in mind from the start!

- We can supply the whole product life-cycle (pre-clinical / clinical / commercial phases) with one Master Cell Bank
- By design we avoid sources of variability (different donors, complex, serum containing media)
- By design we enable adherent and sometimes delicate cell lines to grow well and under fully controlled conditions
- We employ innovative and scalable downstream processing • and analytical tools for EV characterization and product definition

Therefore, if anyone can supply consistent EV / exosome preparations from relevant cell sources – WE CAN



phoenestra

Patent Pending

EVscale[™]: The Novel End-to-end Approach for the Manufacturing of EV-based therapeutics



Cryovial 🛛 Seed train

MSC/TERT* from different human tissues Fully documented and characterized Tiered cell banking possible GMP-ready

Bioreactor cultivation**


Fully controlled bioreactor-based cultivation Consistent EV quality Productive and scalable Fast translation into GMP

Downstream processing

Gentle membrane methods (TFF) Chromatographic separation Scalable and GMPready unit operations


EV characterization


Standard methods Cell-based bioassays NanoFCM RNA sequencing Composition-function relationships



© Nalgene Thermo Fisher Scientific and Phoenestra GmbH








3.00E+11

2,50E+11 2,00E+11 1,50E+11



Get in touch and let us know your thoughts!



Klaus Graumann, CEO and co-founder Phoenestra GmbH klaus.graumann@phoenestra.com

Otto Kanzler, CFO and co-founder Phoenestra GmbH otto.kanzler@phoenestra.com

www.phoenestra.com